Maalox suspension for oral administration sachet 15 ml 30 pcs
Condition: New product
1000 Items
Rating:
Be the first to write a review!
More info
Active ingredients
Algeldrat + Magnesium hydroxide
Release form
Suspension
Composition
15 ml of suspension contains: Active substances: aluminum hydroxide (as gel) 525 mg, magnesium hydroxide (as gel) 600 mg, Auxiliary substances: concentrated hydrochloric acid - 21.3 mg, citric acid monohydrate - 9.83 mg, peppermint leaf oil 1.89 mg, mannitol - 37.5 mg, methyl parahydroxybenzoate - 15 mg, propyl parahydroxybenzoate - 7.5 mg, sodium saccharinate - 4.21 mg, sorbitol 70% - 214.29 mg, hydrogen peroxide 30% - 9.75 mg, purified water - 4746.59 mg.
Pharmacological effect
Antacid medication. Aluminum hydroxide and magnesium hydroxide neutralize the free hydrochloric acid of gastric juice, without causing its secondary hypersecretion. In addition, increasing the pH of gastric juice when taking the drug Maalox leads to a decrease in the activity of pepsin in the gastric juice. The drug also has an adsorbing and enveloping effect, which reduces the effect of damaging factors on the mucous membrane of the esophagus and stomach.
Pharmacokinetics
Magnesium hydroxide and aluminum hydroxide are considered to be local antacids. Due to low absorption do not have a systemic effect.
Indications
Peptic ulcer and duodenal ulcer in the acute phase. Acute gastroduodenitis. Chronic gastroduodenitis with normal or increased secretory function in the acute phase. Hernia of the esophageal opening of the diaphragm. Reflux esophagitis. Phenomena of dyspepsia (and their prevention) resulting from the use of certain drugs (including NSAIDs, GCS). Discomfort or epigastric pain, heartburn with dietary errors, excessive use of coffee, alcohol, nicotine.
Contraindications
Severe renal dysfunction. Hypersensitivity to the drug.
Precautionary measures
On the part of the immune system: the frequency is unknown - hypersensitivity reactions, anaphylactic reactions. Allergic reactions: frequency is unknown - itching, urticaria, angioedema. On the part of the digestive system: infrequently - diarrhea, constipation. On the part of the metabolism: the frequency is unknown - hypermagnesemia, hyperaluminiemia, hypophosphatemia (with long-term treatment or taking in high doses, or when taken in standard doses with a low phosphate content in the diet), which can lead to increased bone resorption, hypercalciuria, osteomalacia.
Use during pregnancy and lactation
To date, no specific teratogenic effects have been identified with the use of Maalox during pregnancy, however, due to insufficient clinical experience with its use in pregnancy, prescribing is possible only if the potential benefit of therapy for the mother justifies the potential risk to the fetus. When using the drug in accordance with the dosing regimen, the absorption of combinations of aluminum hydroxide and magnesium salts in the mother’s body is limited, therefore Maalox is recognized to be compatible with breastfeeding. In preclinical studies in animals, there is no clear indication of the teratogenic effect in aluminum hydroxide and magnesium hydroxide.
Dosage and administration
Adults are prescribed 15 ml (1 tablespoon) of suspension 3-4 times / day. 1-2 hours after meals and overnight. With reflux esophagitis, the drug is taken in a shorter period of time after meals. The duration of treatment should not exceed 2-3 months. For occasional use (for example, for discomfort after errors in the diet) 15 ml of suspension once.
Side effects
On the part of the digestive systemRedko - constipation, nausea, vomiting, changes in taste. Others With prolonged use and in violation of kidney function - an increase in the level of magnesium and / or aluminum in the blood, a deficiency of phosphorus in the body, encephalopathy. in elderly people - exacerbation of diseases of the musculoskeletal system, Alzheimer's disease.
Overdose
Symptoms: diarrhea, abdominal pain and vomiting are possible. In patients at risk, taking high doses of the drug can cause or aggravate intestinal obstruction or intestinal obstruction. Treatment: aluminum and magnesium are excreted in the urine. Losses and forced diuresis are replenished. Patients with renal insufficiency need to undergo hemodialysis or peritoneal dialysis.
Interaction with other drugs
With simultaneous use with quinidine, it is possible to increase serum concentrations of quinidine and develop an overdose of quinidine. When taken simultaneously with the drug Maalox, the following drugs are absorbed from the gastrointestinal tract: histamine H2 receptor blockers, propranolol, atenolol, cefdinir, cefpodoxime, metoprolol, chloroquine,prostacyclin, diflunisal, digoxin, bisphosphonates, ethambutol, isoniazid, cipher quinolones, sodium fluoride, GCS (described for prednisolone and dexamethasone), indomethacin, ketoconazole, lincosamides, neuroleptics derived from phenothiazine, penicilamine, amylaminthyramine, pheniciazine, neuroleptics, pheniciazine, pyricisamine, cytoconazole, linkosamides In the case of a 2-hour interval between taking these drugs and Maalox and the 4-hour interval between taking fluoroquinolones and Maalox, in most cases this unwanted interaction can be avoided. When combined use of the drug Maalox with polystyrenesulfonate (kayeksalat) care should be taken because of the possible risk of reducing the efficiency of potassium binding resin and the development of metabolic alkalosis in patients with renal insufficiency (for aluminum hydroxide and magnesium hydroxide) and intestinal obstruction (for aluminum hydroxide). The combination of aluminum hydroxide with citrates may increase the plasma concentrations of aluminum, especially in patients with renal insufficiency.
special instructions
If during treatment the symptoms of the gastrointestinal tract persist for more than 10 days or a worsening of the condition is observed, then the diagnosis should be clarified and medical measures should be corrected. Observe the 2-hour interval between use of the drug Maalox and other drugs. Despite the fact that the drug is dispensed without a prescription, before using the drug during pregnancy and lactation (breastfeeding), as well as in adolescents and patients with mild to moderate renal insufficiency, it is recommended to consult a doctor. When prescribing Maalox for patients with mild to moderate renal insufficiency, plasma concentrations of aluminum and magnesium should be carefully monitored, and if they are increased, the use of the drug should be immediately discontinued. Algeldrat with a low phosphate content in food can lead to the development of phosphorus deficiency in the body. Therefore, in its application, especially long-term, it is necessary to ensure adequate intake of phosphates from food. Impact on the ability to drive vehicles and control mechanisms: The drug does not affect the ability to drive vehicles and work with mechanisms.